Analyst firms · Robert W. Baird · ARCT

Robert W. Baird ARCT price target and rating history

Arcturus Therapeutics Holdings Inc. (ARCT) · Health Care

Robert W. Baird rates Arcturus Therapeutics Holdings Inc. (ARCT) Underperform with a $18 price target, as of its latest action on Nov 10, 2022. It has published 4 rating actions on ARCT since August 2021, including 1 upgrade and 3 downgrades. Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.

Current rating
Underperform
Price target
$18
Median target, all firms
$20
Actions on ARCT
4

Robert W. Baird price target on ARCT

$31$25$1820222023202420252026
Robert W. Baird price target on ARCT, each point a stated target, August 2021 to November 2022.

Every Robert W. Baird rating on ARCT

How other firms rate ARCT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
CitigroupBuy$20Sep 24, 2026
B. Riley SecuritiesBuy$22Mar 18, 2026
Roth CapitalBuy$20Jan 23, 2026

Questions about Robert W. Baird and ARCT

What is Robert W. Baird's price target for ARCT?
Robert W. Baird's latest stated price target for Arcturus Therapeutics Holdings Inc. (ARCT) is $18, from its action on Nov 10, 2022.
What is Robert W. Baird's rating on ARCT?
Robert W. Baird rates ARCT Underperform, a bearish rating, as of Nov 10, 2022.
When did Robert W. Baird last change its view on ARCT?
On Nov 10, 2022, Robert W. Baird downgrades to Underperform from Neutral, price target $18.
How does Robert W. Baird's ARCT target compare with other analysts?
Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.

More ARCT rating histories

All Robert W. Baird ratingsARCT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.